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Abstract
Background: To evaluate the immunological situation against hepatitis B virus (HBV) of a cohort of dentistry 
students, to analyze the behavior of the levels of hepatitis B surface antigen (anti-HBs) after the administration of 
one or three vaccine doses, and to determine the influence of age and sex on the immune response. 
Material and Methods: This retrospective cohort study included students attending the School of Dentistry of the 
institution where the study was performed from 2005 to 2012 who had completed the public health vaccination 
calendar for HBV at the age of 12-13. Data on age, sex, basal anti-HBs levels, post-vaccination anti-HBs results and 
final anti-HBs levels were collected. Comparisons of the basal and final levels, as well as associations regarding 
age and sex, were performed by means of the Student t and Chi-square tests. 
Results: Of the 359 students, 97 (27.02%) had basal antibody concentrations <10 mIU/ml, whereas in 262 the levels 
of anti-HBs were ≥10 mIU/ml (72.98%). Of the 288 participating students who completed the School s´ protocol for 
immunization, 287 (99.65%) attained a level of protection ≥10 mIU/ml. Globally, there were statistically significant 
differences between the basal antibody levels and those achieved after administration of the vaccine and booster, 
but no association with age or sex was observed. 
Conclusions: About 70% of dental students vaccinated as preadolescents had serologic evidence of protection 
against HBV. Administering a booster is associated with the presence of an excellent immune memory. There is 
clearly a need to reinforce control of the antibody levels in groups at risk, such as Dentistry students.
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Introduction
Infection with the hepatitis B virus (HBV) is a public 
health problem in terms of morbidity and mortality. It is 
estimated that two billion people worldwide have been 
infected with HBV and about 600,000 people die every 
year due to the consequences of hepatitis B, mostly from 
cirrhosis and hepatocellular carcinoma (1).
Strategies for controlling the incidence of HBV infec-
tion combine preventive measures and universal vacci-
nation among newborns and adolescents. After primary 
immunization with the hepatitis B vaccine, the titer of 
antibody to hepatitis B surface antigen (anti-HBs) consi-
dered seroprotective is ≥10 milli-international units per 
milliliter (mIU/ml) (2). The levels of anti-HBs decline 
over time, however, and many people previously vacci-
nated may have anti-HBs below the accepted threshold 
of protection when tested 10-15 years after the primary 
series (3,4). At present there is controversy regarding the 
need to administer an additional vaccine dose (booster) 
in immunocompetent individuals previously vaccinated 
yet whose levels of anti-HBs have decreased due to the 
existence of immune memory (4).
Dentists comprise a high risk group in the face of 
HBV infection, given their frequent exposure to blood 
or body fluids containing HBV. This risk is higher 
during the professional training period (5). Since the 
introduction of obligatory vaccination against HBV for 
healthcare personnel in 1991, the occupational risk in 
dentists has been minimized (6,7). Notwithstanding, 
some individuals are not correctly vaccinated, and a 
low proportion of cases may show failure in the immune 
response (8). Moreover, in Spain, post-vaccination 
serological testing is not carried out; hence it is 
impossible to determine the level of initial response to 
the vaccine, which appears to be the main predictor of 
anti-HBs persistence (9-11). In view of this background, 
the objective of this retrospective study was to evaluate 
the immunological situation against HBV of a cohort 
of students at the School of Dentistry of the institution 
where the study was performed, to analyze the behavior 
of anti-HBs levels after the administration of a full dose 
of vaccine or a booster, and to determine the influence 
of age and sex on immune response.
Material and Methods
This retrospective cohort study was carried out at the 
School of Dentistry. Eligible people were students 
attending from 2005 to 2012 who had completed the 
public health vaccination calendar for HBV at the age 
of 12-13. Data on students regarding age and the sex 
were collected, as well as basal anti-HBs levels, post-
vaccination anti-HBs results and final anti-HBs levels. 
The Ethics Committee of Human Research of the 
institution where the study was performed approved the 
protocol. All subjects signed the informed consent form.
- School of Dentistry Hepatitis B immunization proto-
col
Basal anti-HBs titers were determined through 
chemioluminiscence (Anti-HBs Architect System, 
Abbott, Chicago, USA) when the students were 
attending their second undergraduate year in the 
Dentistry program. According to the basal levels, the 
students were designated as non-immune (anti-HBs <10 
mIU/ml) and immune (anti-HBs ≥10 mIU/ml). On the 
basis of their level of protection, the immune students 
were, in turn, divided into low (anti-HBs 10-99 mIU/
ml), medium (anti-HBs 100-1000 mIU/ml) or high level 
of protection (anti-HBs >1000 mIU/ml). In view of the 
basal levels of anti-HBs, the students with antibodies <10 
mUI/ml received a full vaccine series with three doses 
of Engerix-B 20 µg/ml (GlaxoSmithKline Biologicals, 
Rixensart, Belgium) according to a schedule of 0, 1 and 
6 months. When the levels were 10-99 mIU/ml, just one 
additional vaccine dose was administered. In either case, 
post-vaccination testing was performed three months 
after administration of the last dose. If a student s´ level 
of immunization remained low (anti-HBs 10-99 mIU/
ml) after vaccination with either one or three vaccine 
doses, an additional booster dose was repeated. Post-
vaccination testing was performed three months after 
administration of the booster. Those subjects with basal 
levels of ≥100 mIU/ml were monitored at 2-3 years’ 
time.
- Statistical analysis
All statistical analyses were performed by means of 
SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). 
Descriptive techniques were used for the sample and 
the comparison of means. The Chi-square test was used 
to evaluate the significance of differences in anti-HBs 
levels with regard to age and sex. The Student t-test was 
used to compare the anti-HBs basal and final levels. The 
level of statistical significance was set at P<0.05. The 
presence of immune memory was defined as an anti-
HBs titer ≥4fold greater post- than pre-booster.
Results
The data analyzed were from 359 students attending 
the School of Dentistry during 2005-2012 and who had 
been vaccinated at the age of 10-12 years old. Of the 359 
students, 97 (27.02%) had basal antibody concentrations 
<10 mIU/ml. In 262 the levels of anti-HBs were ≥10 mIU/
ml (72.98%); the concentration was 10-99 mIU/ml in 129 
of these students (35.93%), and it was >100 mIU/ml in 
the remaining 133 (37.05%). The mean age of students 
was 20.09 years, with a standard deviation of 3.26. In 
94.4% the age was less than or equal to 23, and the most 
frequent age was 19 (72.1%). By sex, 262 were female 
(72.9%) and 97 were male (27.01%). The differences 
observed between anti-HBs basal levels and the age and 
sex of participants were not statistically significant. 
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Of the 97 non-immune students (Fig. 1), 92 were 
revaccinated and 87 underwent the post-vaccination 
testing; levels of anti-HBs ≥10 mIU/ml were obtained in 
85 students (97.70%). The two subjects who maintained 
anti-HBs levels <10 mIU/ml did not continue the 
procedure, meaning a fourth dose was not administered 
to them. After administration of a booster to those 
subjects who had had anti-HBs levels in the range 10-
99 mIU/ml after receiving the vaccine, in one case the 
levels dropped to <10 mIU/ml, in two cases the levels 
remained in the same range, and in the rest the levels 
went up to ≥100 mIU/ml. In this group, 14 subjects did 
not complete the protocol.
Fig. 1. Students with basal levels of anti-HBs <10 mIU/ml. Number of students (n) and anti-HBs levels in the different phases of the 
School of Dentistry Hepatitis B immunization procedure. Stage 1: basal anti-HBs levels. Stage 2: vaccination with 3-dose vaccine 
and serologic test 3 months after the last dose. Stage 3: vaccination with one additional vaccine dose when anti-HBs levels were 10-99 
mIU/ml, and serologic test three months after the last dose. 
Meanwhile, in 129 students the basal levels of anti-HBs 
were 10-99 mIU/ml (Fig. 2). Seven of these students 
chose to discontinue the protocol and 122 were given 
one or two boosters, leading to antibody concentrations 
of ≥100 mIU/ml in 121 students (99.18%). 
Finally, out of the 133 students who initially had a basal 
anti-HBs level of ≥100 mIU/ml, 50 did not complete the 
immunization protocol, and of those who finished it, 
65 (78.31%) did so with values between 100 and 1000 
mIU/ml, while the remaining 18 (21.69%) gave levels of 
>1000 mIU/ml (Fig. 3). 
In short, during the study 71 students (19.78%) 
abandoned the procedure in one of its stages. Of the 288 
subjects completing the immunization protocol, 287 
(99.65%) achieved levels of protection of ≥10 mIU/ml: 
three of them (1.04%) attained a low level of protection 
of 10-99 mIU/ml, 115 (39.93%) achieved intermediate 
levels of 100-1000 mIU/ml, and 169 students (58.68%) 
had high protective levels, over 1000 mIU/ml. Globally, 
there were statistically significant differences between 
the basal antibody levels and those obtained after 
administration of the vaccine and booster. The presence 
of immune memory was confirmed in the 145 students 
(96.67%) of a total of 150 that received a booster dose, 
as an increase in antibody levels of 4 times or more was 
observed. 
There were no significant differences in the pattern of 
response after the re-vaccination or the booster dose 
when the findings were distributed by sex and age 
groups (P>0.05). 
Discussion
The prevalence of HBV markers increases over time in 
conjunction with the dental practice of professionals, 
which confirms that there is contact with the virus, and 
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therefore a chance of infection (12). For this reason, it 
is important that dentists be considered at risk and be 
protected during their entire professional careers. The 
immunization protocol at the School of Dentistry of the 
institution aims to monitor and ensure protection against 
HBV before the students actually engage in clinical 
practices at the School (13) or go out into the working 
world (5,14,15). Data were gathered from a total of 359 
undergraduates who had received the HBV vaccine as 
pre-adolescents, but had not undergone post-vaccination 
serologic testing. Such testing is recommended and 
proves cost-effective among healthcare personnel at a 
risk of infection by HBV, since they may often need 
prophylactic measures after accidental percutaneous 
and/or cutaneomucosa exposure (16).
Approximately seven years after their primary vacci-
nation, 72.98% of the students still had detectable an-
tibodies above the seroprotective titer, whereas in the 
other 27.02% the basal level of anti-HBs was below this 
threshold. The decrease in antibody levels may be ex-
Fig. 2. Students with basal levels of anti-HBs 10-99 mIU/ml. Number of students (n) and anti-HBs levels in the different phases of the School 
of Dentistry Hepatitis B immunization procedure. Stage 1: basal anti-HBs levels. Stage 2: vaccination with 1-dose vaccine and serologic test 
three months afterwards. Stage 3: vaccination with one additional vaccine dose when anti-HBs levels were 10-99 mIU/ml and serologic test 
three months after the last dose. 
Fig. 3. Students with basal levels of anti-HBs ≥100 mIU/ml. Number of students (n) and anti-HBs levels in the different phases of the 
School of Dentistry Hepatitis B immunization procedure. Stage 1: basal anti-HBs levels. Stage 2: serologic test 2-3 years afterwards. 
Stage 3: vaccination with one additional vaccine dose when anti-HBs levels were 10-99 mIU/ml, and serologic test three months after 
the last dose. 
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plained by an initial lack of response to the vaccine in 
these particular individuals for such reasons as smoking 
habit, obesity, genetic factors, or immune suppression 
(17-20), or else because they responded to the primary 
3-dose vaccination series but the anti-HBs gradually 
declined over time. It is known that an estimated 13%-
60% of initial responders to the HBV vaccine may lose 
detectable anti-HB in subsequent years (3,5).
Much debate surrounds the number of doses of vaccine 
that should be administered when the levels of anti-
HBs after vaccination are <10 mIU/ml. Some authors 
affirm that a single dose is sufficient to reach the level 
of seroprotection (4), while others insist on the need 
to apply a full dose of vaccine (21,22). Following the 
recommendations by the Centers for Disease Control 
and Prevention for healthcare personnel (5), and because 
the initial response to the vaccine is not known, the 
School of Dentistry protocol specifies revaccination of 
the non-immune students with a triple dose. The level 
of seroprotection obtained in this group was 97.70% 
(85/87). These results are consistent with previous 
studies and evidence the immediate efficacy of the 
vaccine (15,21,22).
The immune students whose levels of anti-HBs were low, 
that is 10-99 mIU/ml, received a dose of vaccine in order 
to attain levels over 100 mIU/ml. The administration of a 
booster dose of vaccine showed a rapid increase, fourfold 
or greater, of the anti-HBs concentration in 145 of the 
150 students in this group. The response to the booster 
dose indicates the presence of an HBV-specific immune 
memory after reception of a vaccine, which is known 
as immune response (11,23). These results confirm 
findings from previous studies, and come to underline 
that there would be no need to administer a booster to 
individuals with low levels of anti-HBs within an interval 
of approximately seven years (4,24). However, several 
studies report cases of failure of the immune memory 15 
years after reception of the primary vaccination series, 
implying that the duration of immune memory is not well 
established (7,25). Such findings urge us to reflect upon 
the need for periodical serologic monitoring of certain 
groups at risk, and the risk groups would clearly include 
healthcare students (26).
The 26.13% of subjects whose anti-HBs basal levels 
were ≥100 mIU/ml showed a decrease in antibodies 2-3 
years later. This finding supports the decay of antibodies 
over time since vaccination (1,27,28) and once again 
points to the importance of controlling anti-HBs levels, 
especially in high-risk groups. Globally, we could not 
establish any gender or age differences in the basal 
levels of anti-HBs or in the immunological response 
to HBV vaccine and booster; other authors arrive at 
similar conclusions (24,29,30). The fact that 72.1% of 
the students were 19 years of age would justify the lack 
of significant differences when comparing the anti-HBs 
levels and age. However, if we compare the final levels 
of anti-HBs and sex, women show a somewhat higher 
level of protection than men.
The drop out rate of the serological immunization pro-
tocol was found to be greater among the subjects with 
basal anti-HBs titers ≥100 mIU/ml, which is logical 
in view of their high level of protection against HBV 
infection. Of the 288 students who completed the im-
munization procedure, 287 (99.65%) exhibited a level 
of antibodies over the seroprotective threshold, and 284 
of these (98.61%) had a concentration of ≥100 mIU/ml. 
Noteworthy is the case of one non-immune student who, 
after administration of a 3-dose vaccine followed by a 
booster, gave anti-HBs levels under the seroprotective 
threshold. The absence of HBsAg was confirmed. This 
poor immune response could have to do with immuno-
suppression or with genetic factors (16,18,19).
A limitation of this study that must be addressed is that 
data on initial vaccination against HBV was collected 
by self-report, and was not verified by medical records; 
this introduces a possibility of bias in the basal antibody 
levels registered. 
Conclusions
Within the limitations of this study, our findings in-
dicate that about 70% of students vaccinated as pre-
adolescents showed serologic evidence of protection 
against HBV after approximately seven years. Moreo-
ver, almost all non-immune students were seroprotected 
after re-vaccination. Administering a booster is associ-
ated with the presence of an excellent immune memory 
in most vaccinees. Thus far we are not certain of the 
clinical relevance of immune memory, however. There 
is clearly a need to reinforce control of the antibody lev-
els in groups at risk, such as Dentistry students.
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